Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

GlaxoSmithKline (GSK - Analyst Report) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on its cervical cancer vaccine, Cervarix.

Glaxo is looking to get a two-dose schedule of Cervarix approved for use in girls between 9 to 14 years for the prevention of premalignant genital lesions including cervical, vulvar and vaginal and cervical cancer causally related to certain oncogenic Human Papillomavirus types. Glaxo submitted a Marketing Authorisation Application (MAA) to the EMA for the same in Aug 2013.

The MAA was based on data from a phase III study, in which the use of Cervarix (two-dose schedule) in girls between 9 to 14 years demonstrated comparable benefit in terms of immunogenicity to the three-dose schedule of the drug in girls aged between 15 to 25 years.

Currently, a three-dose schedule of Cervarix is approved in the EU for the above mentioned indication in girls above 9 years.

Meanwhile, a few days back, Glaxo’s pandemic Influenza A (H5N1) virus monovalent vaccine, adjuvanted (Q-Pan H5N1 influenza vaccine) received approval from the U.S. Food and Drug Administration (FDA). The FDA approved the vaccine for immunization of adults for the prevention of disease caused by the influenza A virus H5N1 subtype present in the vaccine.

Influenza A (H5N1) virus monovalent vaccine, adjuvanted, is also approved in Europe under the trade name Pumarix.

We note that Glaxo boasts of a strong vaccine portfolio, which includes vaccines like Infanrix/Pediarix, Rotarix, Synflorix and Cervarix. Glaxo has a strong vaccine segment, which generated sales of £2.5 billion in the first nine months of 2013, approximately 12.5% of the total product sales of the company.

Glaxo carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Actelion Ltd. (ALIOF), Jazz Pharmaceuticals (JAZZ - Analyst Report) and Bayer (BAYRY - Analyst Report). While Actelion and Jazz Pharma carry a Zacks Rank #1 (Strong Buy), Bayer holds a Zacks Rank #2 (Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.97 +17.30%
ATLAS FINANC AFH 14.57 +2.32%
FEDERATED NA FNHC 20.25 +1.91%
GREEN PLAINS GPRE 29.43 +1.66%
PIONEER ENER PES 14.06 +1.30%